Serum IL-8 and IL-12 levels in breast cancer


Derin D., SOYDINC H. O. , Güney N., Tas F. , Çamlıca H. , Duranyıldız D. , ...More

MEDICAL ONCOLOGY, vol.24, no.2, pp.163-168, 2007 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 2
  • Publication Date: 2007
  • Doi Number: 10.1007/bf02698035
  • Title of Journal : MEDICAL ONCOLOGY
  • Page Numbers: pp.163-168
  • Keywords: breast cancer, chemotherapy, IL-8, IL-12, serum, INTERLEUKIN-10 PRODUCTION, OVARIAN-CANCER, CELLS, ANGIOGENESIS, EXPRESSION, CYTOKINES

Abstract

Interleukins (ILs) are known to play a fundamental role in cancer. We investigated the serum levels of IL-8 and IL-12, in breast cancer patients, and their relationship with the prognostic parameters and therapy. Forty-eight patients with pathologically verified breast carcinoma and 21 healthy controls were enrolled into the study. Serum samples were obtained at baseline and after two cycles of chemotherapy. Serum IL-8 and IL-12 levels were determined using enzyme-linked immunosorbent assay (ELISA). There was no significant difference in the baseline serum L-8 and IL-12 levels between breast cancer patients and healthy controls (p = 0.365 and p = 0.871, respectively), no significant correlation between the prognostic parameters and the serum IL-8, IL-12 levels. However, in the subgroup consisting of metastatic breast cancer patients, baseline serum IL-8 levels were significantly higher compared with non-metastatic disease (p = 0.047). Anthracycline-based chemotherapy and the addition of taxane did not change the levels of both serum IL-8 and IL-12. Serum IL-8 level may be useful in determining metastatic breast cancer. Larger studies are needed to confirm this finding.